TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26729395

Group type: EXPERIMENTAL
Intervention: Screening and health assessments for high-risk CVD subjects including ECG, ultrasound scan, blood and urine analysis, and lifestyle questionnaire.
Number of subjects: 400000

Group type: EXPERIMENTAL
Intervention: Follow-up assessments including blood pressure, weight, ECG, and questionnaires on survival status, hospitalisations, and lifestyle.
Number of subjects: 400000

Group type: EXPERIMENTAL
Intervention: Preliminary analysis of the first 0.1 million participants screened.
Number of subjects: 400000
Study: 26729445

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 1754
Study: 26729653

Group type: EXPERIMENTAL
Intervention: Various immunosuppressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic exposure to alloantigen from allografts
Number of subjects: 0
Study: 26729855

Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NIRS in pre-existing stents
Number of subjects: 60
Study: 26731175

Group type: EXPERIMENTAL
Intervention: TFV/FTC with EFV
Number of subjects: 79
Study: 26731755

Group type: EXPERIMENTAL
Intervention: 1% topical cidofovir cream applied intraanally three times per week for 4 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1% topical cidofovir cream
Number of subjects: 17
Study: 26732570

Group type: EXPERIMENTAL
Intervention: Three-dimensional pseudocontinuous arterial spin labeling with postlabeling delays of 1.5 s and 2.5 s
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Three-dimensional pseudocontinuous arterial spin labeling
Number of subjects: 41
Study: 26733541

Group type: EXPERIMENTAL
Intervention: Nasal high flow (nHF)
Number of subjects: 28
Study: 26733671

Group type: EXPERIMENTAL
Intervention: QUAD therapy with daclatasvir (DCV), asunaprevir (ASV), PegIFN, and RBV
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DCV/ASV regimen
Number of subjects: 22

Group type: COMPARATOR
Intervention: PegIFN/RBV therapy
Number of subjects: 22
Study: 26734580

Group type: EXPERIMENTAL
Intervention: Oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (20 mg/m(2) on days 1 and 8) and 5-FU (330 mg/m(2) continuously on days 1-5 and 8-12) via an implanted catheter system.
Number of subjects: 18
Study: 26735686

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 10
Study: 26735992

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (200 to 250 ml transfusions, 2 consecutive transfusions)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (418 patients treated during the previous 5 months)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 99
Study: 26736064

Group type: EXPERIMENTAL
Intervention: Exome sequencing analysis in families with severe COPD
Number of subjects: 347

Group type: COMPARATOR
Intervention: Exome sequencing analysis in cases with severe COPD
Number of subjects: 347
Study: 26736871

Group type: EXPERIMENTAL
Intervention: Univariate and multivariate analyses to predict mortality in the following 7 days
Number of subjects: 23
Study: 26738624

Group type: EXPERIMENTAL
Intervention: Cervical decompressive surgery
Number of subjects: 50
Study: 26738669

Group type: EXPERIMENTAL
Intervention: P2Y12 reaction units (PRU) quintile 5 (most inhibited)
Number of subjects: 8582

Group type: COMPARATOR
Intervention: P2Y12 reaction units (PRU) quintile 1 (least inhibited)
Number of subjects: 8582
Study: 26738949

Group type: EXPERIMENTAL
Intervention: Sodium restricted (<2,500 mg/d)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Sodium unrestricted (≥2,500 mg/d)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Sodium restricted (<2,500 mg/d) in patients not receiving ACE inhibitors or ARBs
Number of subjects: 902
Study: 26739033

Group type: EXPERIMENTAL
Intervention: Standardized breakfast followed by a standardized meal
Number of subjects: 42
Study: 26739478

Group type: EXPERIMENTAL
Intervention: Modified endaural approach
Number of subjects: 75
Study: 26739719

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (CT) infection
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae (NG) infection
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 718
Study: 26739730

Group type: EXPERIMENTAL
Intervention: Varenicline and counselling
Number of subjects: 924

Group type: COMPARATOR
Intervention: Counselling only
Number of subjects: 924
Study: 26739732

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily for 21 days preoperatively
Number of subjects: 35
Study: 26740638

Group type: COMPARATOR
Intervention: Mediterranean Diet
Number of subjects: 0
Study: 26740893

Group type: EXPERIMENTAL
Intervention: 5 mg/day desloratadine for 4 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 5 mg/day levocetirizine for 4 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both H1 antihistamines
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Levocetirizine and desloratadine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: House dust sensitization
Number of subjects: 85
Study: 26740901

Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI) with b factor of 1000 s/mm(2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: T2 weighted images
Number of subjects: 48
Study: 26741046

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette smoke (CS) exposure
Number of subjects: 0
Study: 26741949

Group type: EXPERIMENTAL
Intervention: Enteral feeding systems (using mother's own milk, donor milk, and preterm formula)
Number of subjects: 26
Study: 26742009

Group type: COMPARATOR
Intervention: Statin use (any statin at baseline)
Number of subjects: 118357

Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 118357

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 118357

Group type: COMPARATOR
Intervention: Lipophilic statins
Number of subjects: 118357

Group type: COMPARATOR
Intervention: Low and high potency statins
Number of subjects: 118357
Study: 26743093

Group type: EXPERIMENTAL
Intervention: Simeprevir
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: PHOTON-1
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: TURQUOISE-I
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: ION-4
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: ALLY-2
Number of subjects: 874
Study: 26743463

Group type: EXPERIMENTAL
Intervention: Optical coherence tomographic assessment of coronary calcification in patients with ST-segment-elevation myocardial infarction
Number of subjects: 108

Group type: COMPARATOR
Intervention: Optical coherence tomographic assessment of coronary calcification in patients with stable angina pectoris
Number of subjects: 108
Study: 26744120

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 90

Group type: COMPARATOR
Intervention: TD group
Number of subjects: 90
Study: 26745007

Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Number of subjects: 19
Study: 26745476

Group type: EXPERIMENTAL
Intervention: Bilateral thalamic stimulation for a minimum of 18 months and a maximum of 48 months.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 40
Study: 26745506

Group type: EXPERIMENTAL
Intervention: Admixture-adjusted, genotype-guided warfarin dosing algorithm
Number of subjects: 255

Group type: COMPARATOR
Intervention: Clinical algorithm excluding genotypes and admixture
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Admixture-driven pharmacogenetic algorithm (external validation)
Number of subjects: 255
Study: 26745574

Group type: EXPERIMENTAL
Intervention: Placental matrix-derived mesenchymal stem cells (PM-MSCs) injection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 26745686

Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions about the self and self-blame
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Comorbid depressive symptoms
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Potential pathway from posttraumatic cognitions to PTSD
Number of subjects: 150
Study: 26745856

Group type: EXPERIMENTAL
Intervention: 0.3 parts per million ozone for 2 hours during 15-minute on-off exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 24
Study: 26746120

Group type: EXPERIMENTAL
Intervention: Unilateral micro-testicular sperm extraction
Number of subjects: 15

Group type: COMPARATOR
Intervention: None (control group with no sperm in ejaculates)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Scrotal and renal ultrasound imaging
Number of subjects: 15
Study: 26746629

Group type: EXPERIMENTAL
Intervention: Gene-expression profiling (GEP) test (AlloMap®)
Number of subjects: 399
Study: 26746910

Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - active motion
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - hip stability
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - motor control
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - flexibility and power
Number of subjects: 359

Group type: COMPARATOR
Intervention: Known risk factors (age, BMI, gender, excessive flexibility, past injury)
Number of subjects: 359
Study: 26747086

Group type: EXPERIMENTAL
Intervention: Anthracycline doses of 250 mg/m2 or more
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Heart radiation exposure
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Radiation exposure greater than 1500 cGy with any anthracycline exposure
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Overall cardiovascular screening
Number of subjects: 1853
Study: 26747132

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) for uncomplicated malaria
Number of subjects: 0
Study: 26748219

Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty (ESG)
Number of subjects: 25
Study: 26748221

Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD) for 6 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD) continued long-term
Number of subjects: 41
Study: 26748954

Group type: EXPERIMENTAL
Intervention: Baseline serum hsCRP quartiles
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Higher baseline hsCRP
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Change in hsCRP
Number of subjects: 192
Study: 26748972

Group type: EXPERIMENTAL
Intervention: Infanrix hexa (DTPa-HBV-IPV/Hib) vaccine reimbursement
Number of subjects: 4903
Study: 26749066

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for RARS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for CRSsNP
Number of subjects: 40
Study: 26749226

Group type: EXPERIMENTAL
Intervention: Interferon-γ/interleukin-17-producing cells in peripheral blood and skin during acute cellular rejection
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Serum monocyte chemotactic protein-1 level
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: T follicular helper cells
Number of subjects: 6
Study: 26751375

Group type: EXPERIMENTAL
Intervention: Completely vaccinated
Number of subjects: 1583042

Group type: EXPERIMENTAL
Intervention: Incompletely vaccinated
Number of subjects: 1583042

Group type: COMPARATOR
Intervention: Contemporarily unvaccinated
Number of subjects: 1583042

Group type: COMPARATOR
Intervention: Historically unvaccinated
Number of subjects: 1583042
Study: 26751506

Group type: EXPERIMENTAL
Intervention: Weight loss (decreasing BMI)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Weight gain (increasing BMI)
Number of subjects: 1673

Group type: COMPARATOR
Intervention: Weight stability (stable BMI)
Number of subjects: 1673

Group type: COMPARATOR
Intervention: Survival analysis among BMI trajectory groups
Number of subjects: 1673
Study: 26751952

Group type: EXPERIMENTAL
Intervention: Aerobic training on a stationary bike for 30 minutes, three times weekly, for 10 weeks at 70% of VO2max.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-intervention group (n = 7).
Number of subjects: 16
Study: 26752024

Group type: EXPERIMENTAL
Intervention: Doubling dose of Salmeterol and Fluticasone Propionate for 10 days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Antibiotic for 5 days (for purulent exacerbations)
Number of subjects: 37
Study: 26752061

Group type: EXPERIMENTAL
Intervention: hsa-miR-1246 quantified by real-time PCR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) technology
Number of subjects: 0
Study: 26752222

Group type: EXPERIMENTAL
Intervention: Temporary extracorporeal perfusion of flaps maintained for 10-13 days
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Systemic transfusion of packed red cells
Number of subjects: 3
Study: 26753096

Group type: EXPERIMENTAL
Intervention: Salivary cortisol (SaC) levels in high STC group on Day 1: 2.3 (0.2-9.0) μg/dL; Day 7: 1.1 (0.8-4.6) μg/dL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salivary cortisol (SaC) levels in control group: Baseline: 0.4 (0.1-1.4) μg/dL; Peak: 1.1 (0.4-2.5) μg/dL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calculated free cortisol (cFC) levels in high STC group on Day 1: 0.3 (0.1-0.3) μg/dL; Day 7: 0.2 (0.1-0.3) μg/dL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calculated free cortisol (cFC) levels in control group: Baseline: 1.7 (0.4-1.9) μg/dL; Peak: 1.8 (1.0-6.6) μg/dL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serum total cortisol (STC) levels
Number of subjects: 30
Study: 26753774

Group type: EXPERIMENTAL
Intervention: simeprevir + PegIFNα-2a + RBV
Number of subjects: 12

Group type: COMPARATOR
Intervention: PegIFNα-2a + RBV
Number of subjects: 12
Study: 26754175

Group type: EXPERIMENTAL
Intervention: Qualitative insights from GPs and community members regarding antibiotic prescribing and consumption for UTI.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Qualitative research methodology.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Complex intervention informed by social marketing.
Number of subjects: 57
Study: 26755520

Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) administered intravenously every 3 weeks
Number of subjects: 70
Study: 26755709

Group type: EXPERIMENTAL
Intervention: Blinatumomab (stepwise dosing: 9-28-112 μg/d with weekly dose increases)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Blinatumomab (flat dosing: 112 μg/d)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Blinatumomab (stepwise dosing)
Number of subjects: 25
Study: 26755710

Group type: EXPERIMENTAL
Intervention: Prophylaxis with rIX-FP 40 IU/kg weekly
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Prophylaxis with rIX-FP 75 IU/kg every 2 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: On-demand treatment for bleeding episodes
Number of subjects: 63
Study: 26755711

Group type: EXPERIMENTAL
Intervention: MRD plasma cells
Number of subjects: 40
Study: 26755712

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (90 mg/m(2))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose daunorubicin (45 mg/m(2))
Number of subjects: 0
Study: 26756117

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 1 and type 2 diabetes patients
Number of subjects: 0
Study: 26756119

Group type: EXPERIMENTAL
Intervention: HIV subjects with long-duration antiretroviral use
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HIV subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HIV subjects with excess DCAT
Number of subjects: 18
Study: 26756872

Group type: EXPERIMENTAL
Intervention: Maternal microchimerism screening in lymph nodes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maternal microchimerism screening in infants' peripheral blood
Number of subjects: 6
Study: 26757199

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26757728

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Active Control (psycho-education and relaxation techniques)
Number of subjects: 88
Study: 26757786

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 13662

Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapies
Number of subjects: 13662

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 13662

Group type: EXPERIMENTAL
Intervention: In-hospital major adverse cardiac and cerebrovascular events
Number of subjects: 13662

Group type: EXPERIMENTAL
Intervention: Charlson score ≥2 in patients treated with PCI
Number of subjects: 13662
Study: 26758264

Group type: EXPERIMENTAL
Intervention: Preoperative risk score for potentially preventable 'medical' complications
Number of subjects: 8373

Group type: EXPERIMENTAL
Intervention: Preoperative characteristics associated with potentially preventable 'medical' complications
Number of subjects: 8373

Group type: EXPERIMENTAL
Intervention: Patients with ≥ 2 of the following characteristics: age ≥ 80 years, anticoagulant therapy, pulmonary disease, pharmacologically treated psychiatric disorder, anaemia, and walking aids
Number of subjects: 8373

Group type: EXPERIMENTAL
Intervention: Hypothetical intervention leading to 25% reduction in potentially preventable 'medical' complications
Number of subjects: 8373

Group type: EXPERIMENTAL
Intervention: THA, use of walking aids and cardiac disease
Number of subjects: 8373

Group type: EXPERIMENTAL
Intervention: Preoperative identification of patients at high risk of preventable 'medical' complications
Number of subjects: 8373
Study: 26758536

Group type: EXPERIMENTAL
Intervention: SPARCS
Number of subjects: 93

Group type: COMPARATOR
Intervention: Pelli-Robson (PR)
Number of subjects: 93
Study: 26758543

Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CAG) performed
Number of subjects: 798

Group type: COMPARATOR
Intervention: No Coronary Angiography (CAG) performed
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Multivessel Coronary Artery Disease (CAD) with CAG performed
Number of subjects: 798

Group type: COMPARATOR
Intervention: Non-performance of CAG
Number of subjects: 798
Study: 26758560

Group type: EXPERIMENTAL
Intervention: cfDNA analysis using next-generation sequencing for 50 cancer genes
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 334
Study: 26758879

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily for 2 years
Number of subjects: 42
Study: 26759718

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) for 10 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Interpersonal effectiveness skills training (IE) for 10 weeks
Number of subjects: 64
Study: 26759992

Group type: EXPERIMENTAL
Intervention: Discontinuation of antipsychotic medication (N=46)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Maintenance on prescribed antipsychotic medication (N=22)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall group of relapsed individuals (N=38)
Number of subjects: 68
Study: 26761266

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 151
Study: 26761269

Group type: EXPERIMENTAL
Intervention: Seminal plasma-derived IgG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Enriched IgG
Number of subjects: 11
Study: 26761707

Group type: EXPERIMENTAL
Intervention: H3N2 influenza challenge virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different inoculum titres of H3N2 virus
Number of subjects: 0
Study: 26761784

Group type: EXPERIMENTAL
Intervention: Capecitabine-based anticancer regimens
Number of subjects: 1463
Study: 26762240

Group type: EXPERIMENTAL
Intervention: RVLS < |13|%
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: RVLS > |13|%
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Rest RVLS < |13|%
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Stress RVLS < |14|%
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Stress RVLS < |14|% after adjustment for rest RVLS
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Rest RVLS
Number of subjects: 211
Study: 26762316

Group type: EXPERIMENTAL
Intervention: i-Scan endoscopy (SE)
Number of subjects: 138
Study: 26762363

Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose inactivated influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemagglutination inhibition assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virus neutralization test titers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme-linked lectin assay for antineuraminidase N2 antibodies
Number of subjects: 0
Study: 26762403

Group type: EXPERIMENTAL
Intervention: Basic brain health self-management information
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Specific, more intensive interventions (pilot studies)
Number of subjects: 900
Study: 26762579

Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg daily
Number of subjects: 81
Study: 26763281

Group type: EXPERIMENTAL
Intervention: Myocardial hemorrhage 2 days post MI
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Myocardial hemorrhage
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Microvascular obstruction
Number of subjects: 286
Study: 26763495

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 228
Study: 26763552

Group type: EXPERIMENTAL
Intervention: Serum AMH levels measured using Beckman Coulter Gen II assay
Number of subjects: 1590

Group type: EXPERIMENTAL
Intervention: Correlation analysis of AMH with other clinical markers
Number of subjects: 1590
Study: 26764356

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (50 mg/kg per day on days 3 and 4 after transplantation)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 43